Novel Approaches to Selective Treatments of Human Solid Tumors: Laboratory and Clinical Correlation

Front Matter....Pages i-xii
5-Fluoro-2′-Deoxyuridine: Role of Schedule in its Therapeutic Efficacy....Pages 1-8
Comparison of Continuous Infusions and Bolus Injections of 5.Fluorouracil with or without Leucovorin: Implications for Inhibition of Thymidylate Synthase....Pages 9-21
Cellular Interactions Between the Natural and Unnatural Isomers of 5-Formyltetrahydrofolate....Pages 23-30
Leucovorin as a Prodrug....Pages 31-42
Clinical Use of Leucovorin: Intracellular Metabolism....Pages 43-49
Some Considerations Concerning the Dose and Schedule of 5FU and Leucovorin: Toxicities of two Dose Schedules from the Intergroup Colon Adjuvant Trial (INT-0089)....Pages 51-56
Effects of 5-Fluorouracil on mRNA....Pages 57-65
Genetic Variation in Thymidylate Synthase Confers Resistance to 5-Fluorodeoxyuridine....Pages 67-76
Experience with 5FU + L-Leucovorin....Pages 77-79
5-Fluorouracil Combined with the Pure [6S]-Stereoisomer of Folinic Acid in High Doses for Treatment of Patients with Advanced Colorectal Carcinoma: A Phase I–II Study of two Consecutive Regimens....Pages 81-98
5-Fluorouracil Modulation in Colorectal Carcinoma Experience of German Investigators....Pages 99-107
An Overview of Adjuvant Treatment of Colon Cancer....Pages 109-118
Dose-Dependent Inhibition of Aspartate Carbamoyltransferase in Peripheral Blood Mononuclear Cells in Patients Receiving N-(Phosphonacetyl)-L-Aspartate....Pages 119-123
Increasing the Efficacy of 5-Fluorouracil with Interferons: Preclinical, Clinical, and Pharmacokinetic Studies....Pages 125-131
Enhanced Cytotoxicity of 5-Fluorouracil Combined with [6RS]Leucovorin and Recombinant Human Interferon-α2a in Colon Carcinoma Cells....Pages 133-142
Regulation of Thymidylate Synthase in Human Colon Cancer Cells Treated with 5-Fluorouracil and Interferon-Gamma....Pages 143-151
Biochemical Modulation of 5-Fluorouracil by Pala: Mechanism of Action....Pages 153-167
Implications of Chronobiology for 5-Fluorouracil (5-Fu) Efficacy....Pages 169-186
Fluorouracil and Leucovorin in Advanced Breast Cancer....Pages 187-195
Fluorouracil Modulation in Head and Neck Cancer....Pages 197-208
Biomodulation in Head and Neck Carcinomas: Therapeutic Approaches in Europe....Pages 209-221
Rationale for the Combination Therapy of 5FU and CDDP....Pages 223-231
Biochemical Modulation of Fluoropyrimidines: the “Giscad” Studies....Pages 233-241
Clinical Experience with UFT in Japan....Pages 243-251
Clinical Studies of the Modulation of Ftorafur....Pages 253-263
The Role of the Reduced-Folate Carrier and Metabolism to Intracellular Polyglutamates for the Activity of ICI D1694....Pages 265-276
The History of the Development and Clinical Use of CB 3717 and ICI D1694....Pages 277-290
P53: A Determinant of the Cell Cycle Response to DNA Damage....Pages 291-296
Therapeutic Implications of Molecular Genetics....Pages 297-304
Summary....Pages 305-309
Back Matter....Pages 311-319